Researcher
Peter Van Dam
- Research Expertise:Translational investigations in breat and cervical cancer Immune environment in inflammatory breast cancer and cervical cancer Effect of Denosumab on the immune environment of cervical cancer Quality control of cancer treatment Telemonitoring of sidde effects of cancer treatment Cognitive impairment after cancer treatment
- Keywords:T CYTOTOXIC LYMPHOCYTE, T HELPER LYMPHOCYTE, Medicine
- Disciplines:Cancer biology, Cancer diagnosis, Cancer therapy
- Research techniques:Immunohistochemical staining Flow cytometry RNA seq
- Users of research expertise:Other interested groups
Affiliations
- Center for Oncological Research (CORE) (Research group)
Member
From1 Jan 2019 → Today - Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO) (Research group)
Member
From1 Feb 2014 → 31 Dec 2018
Projects
1 - 9 of 9
- Reinvigorating the antitumor immunity in human breastand cervical cancer with an innovative RANK(L) targeted combination strategy.From1 Nov 2021 → TodayFunding: Nonprofit institution or equivalents
- Development and validation of a novel rationally designed immunotherapeutic combination strategy built upon targeting RANK(L) for cervical cancer.From1 Nov 2020 → TodayFunding: FWO Strategic Basic Research Grant
- Acquired immunity and immunologic aspects of SARS-CoV-2 infection a population of patients and healthcare workers in Multidisciplinary Oncologic Centres. (MOCOR-Study).From1 Jun 2020 → 31 May 2021Funding: BOF - projects
- Unveiling the drug repurposing versatility of denosumab in the battle against human cervical cancer.From1 Jan 2020 → 31 Dec 2020Funding: Nonprofit institution or equivalents
- Integrated Personalized & Precision Oncology Network (IPPON).From1 Jan 2020 → TodayFunding: BOF - research organisations, Fund Recuperation Fiscal Exemption
- The role of infiltrating immune cells in the aggresive phenotype of inflammatory breast cancer and possible new (immuno)therapeutic targets.From1 Oct 2018 → 30 Sep 2020Funding: FWO fellowships
- RANK signaling and checkpoint inhibition.From15 Sep 2018 → 14 Sep 2021Funding: Nonprofit institution or equivalents
- The role of infiltrating immune cells in the aggresive phenotype of inflammatory breast cancer and possible new (immuno)therapeutic targets.From1 Oct 2016 → 30 Sep 2018Funding: FWO fellowships
- Characterization of the stromal component in inflammatory breast cancer.From15 Jan 2016 → 14 Jan 2017Funding: Nonprofit institution or equivalents
Publications
1 - 10 of 107
- Treatment and outcomes in breast cancer patients(2024)
Authors: Cynthia Aristei, Mariano Tomatis, Antonio Ponti, Lorenza Marotti, Maria Joao Cardoso, Kwok Leung Cheung, Giuseppe Curigliano, Jakob De Vries, Donatella Santini, Francesco Sardanelli, et al.
Pages: 1 - 6 - Implementation of PROs in daily oncology care before and during the SARS-CoV-2 pandemic(2023)
Authors: Marika Rasschaert, Marc Peeters, Peter Van Dam, Annelies J R Janssens
Number of pages: 120 - Urine as a liquid biopsy for cancer detection(2023)
Authors: Stephanie Jordaens, Patrick Pauwels, Wiebren Tjalma, Alex Vorsters, Vanessa Vankerckhoven, Christophe Deben, Karen Zwaenepoel, Peter Van Dam, Stefan De Wachter
Number of pages: 265 - Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in patients with cancer(2023)
Authors: Yana Debie, Jonas Van Audenaerde, Timon Vandamme, Lieselot Croes, Laure-Anne Teuwen, Greetje Vanhoutte, Elly Marcq, Lisa Verheggen, Debbie Le Blon, Maria Goossens, et al.
Pages: 635 - 646 - Boosting capacity of a fourth dose BNT162b2 in cancer patients(2023)
Authors: Yana Debie, Peter Van Dam, Maria Goossens, Marc Peeters, Timon Vandamme
Pages: 121 - 123 - Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1)(2023)
Authors: S. Lot Aronson, Marta Lopez-Yurda, Simone N. Koole, Jules H. Schagen van Leeuwen, Hendrik W.R. Schreuder, Ralph H.M. Hermans, Ignace H.J.T. de Hingh, Mignon D.J.M. van Gent, Henriette J.G. Arts, Maaike A.P.C. van Ham, et al.
Pages: 1109 - 1118 - Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma(2023)
Authors: Emiel A. De Jaeghere, Sandra Tuyaerts, An M.T. Van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens, Peter Vuylsteke, Stephanie Henry, Xuan Bich Trinh, et al.
Pages: 475 - 491 - Association between hospital volume and outcomes in invasive ovarian cancer in Belgium(2023)
Authors: Isabelle Savoye, Geert Silversmit, Jolyce Bourgeois, Cindy De Gendt, Roos Leroy, Hanna M. Peacock, Sabine Stordeur, Philippe de Sutter, Frederic Goffin, Mathieu Luyckx, et al.
Pages: 1 - 6 - The immune microenvironment characterisation and dynamics in hormone receptor-positive breast cancer before and after neoadjuvant endocrine therapy(2023)
Authors: Gizem Öner, Christophe Van Berckelaer, Karen Zwaenepoel, Sevilay Altintas, Zafer Canturk, Wiebren Tjalma, Zwi Berneman, Marc Peeters, Patrick Pauwels, Peter Van Dam
Pages: 17901 - 17913 - The impact of the SARS-COV-2 pandemic on the quality of breast cancer care in EUSOMA-certified breast centres(2022)
Authors: Peter Van Dam, Mariano Tomatis, Antonio Ponti, Lorenza Marotti, Cynthia Aristei, Laura Biganzoli, Maria J. Cardoso, Kwok L. Cheung, Giuseppe Curigliano, Jakob De Vries, et al.
Pages: 72 - 79